Imexon

Generic Name: Imexon

Drug Type: Small Molecule

Chemical Formula: C_₄H_₅N_₃O

CAS Number: 59643-91-3

Unique Ingredient Identifier: 8F63U28T2V

Background: Imexon is currently being studied for the treatment of pancreatic, lung, breast, prostate, melanoma, and multiple myeloma cancers. It belongs to the family of drugs called cyanoaziridine derivatives. Also called Amplimexon. Imexon is a cyanoaziridine derivative.

Imexon is a thiol-binding small molecule which induces mitochondrial oxidation, a loss of membrane potential and cytochrome C, leading to apoptosis.

Indication: Investigated for use/treatment in melanoma, multiple myeloma, ovarian cancer, pancreatic cancer, and solid tumors.

Clinical Trials

Imexon for Relapsed Follicular and Aggressive Lymphomas

Phase 2

Completed

Conditions: Small Lymphocytic Lymphoma
Marginal Zone Lymphoma
Diffuse Large B Cell Lymphoma
Follicular Lymphoma
Mantle Cell Lymphoma
Lymphoplasmacytic Lymphoma
Burkitt's Lymphoma

Interventions: Drug: Imexon

First Posted Date: 2011-03-14

Last Posted Date: 2016-01-06

Lead Sponsor: University of Rochester

Target Recruit Count: 22

Registration Number: NCT01314014

Locations: 🇺🇸
Arizona Cancer Center, University of Arizona, Tucson, Arizona, United States
🇺🇸
University of Rochester Medical Center, Rochester, New York, United States

A Safety and Efficacy Trial of Amplimexon Plus Taxotere in Metastatic Non-Small Cell Lung Cancer

Phase 2

Withdrawn

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Imexon + docetaxel

First Posted Date: 2008-06-13

Last Posted Date: 2015-06-24

Lead Sponsor: AmpliMed Corporation

Registration Number: NCT00697060

Locations: 🇺🇸
USC Norris Cotton Cancer Center, Los Angeles, California, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Mary Crowley Research Center, Dallas, Texas, United States

A Randomized Study of Amplimexon (Imexon) With Gemcitabine in Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Neoplasms

Interventions: Drug: imexon in combination with gemcitabine
Drug: imexon placebo + gemcitabine

First Posted Date: 2008-03-17

Last Posted Date: 2019-03-20

Lead Sponsor: AmpliMed Corporation

Target Recruit Count: 142

Registration Number: NCT00637247

Locations: 🇺🇸
Cancer Center of North Carolina- US Oncology, Raleigh, North Carolina, United States
🇺🇸
Central Indiana Cancer Centers- US Oncology, Indianapolis, Indiana, United States
🇺🇸
Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States

and more 44 locations

Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients

Phase 1

Completed

Conditions: Non-small Cell Lung Cancer
Breast Cancer
Prostate Cancer

Interventions: Drug: imexon
Drug: docetaxel

First Posted Date: 2006-05-18

Last Posted Date: 2015-06-24

Lead Sponsor: AmpliMed Corporation

Target Recruit Count: 34

Registration Number: NCT00327288

Locations: 🇺🇸
Investigational Site 008, Houston, Texas, United States

Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma

Phase 1

Completed

Conditions: Pancreatic Adenocarcinoma

First Posted Date: 2006-05-18

Last Posted Date: 2010-09-15

Lead Sponsor: AmpliMed Corporation

Target Recruit Count: 105

Registration Number: NCT00327327

Locations: 🇺🇸
US Oncology Albany, New York Oncology, Albany, New York, United States
🇺🇸
US Oncology Orlando, Cancer Centers of FL, Ocoee, Florida, United States
🇺🇸
US Oncology Kettering, Kettering, Ohio, United States

and more 6 locations

Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma

Phase 1

Completed

Conditions: Malignant Melanoma

Interventions: Drug: imexon
Drug: DTIC

First Posted Date: 2006-05-18

Last Posted Date: 2010-09-15

Lead Sponsor: AmpliMed Corporation

Target Recruit Count: 68

Registration Number: NCT00327600

Locations: 🇺🇸
University of CO Anschutz Cancer Pavilion, Aurora, Colorado, United States
🇺🇸
Investigational Site 012, Salt Lake City, Utah, United States
🇺🇸
US Oncology Greenville, Cancer Centers of the Carolinas, Greenville, South Carolina, United States

and more 8 locations

Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients

Phase 1

Completed

Conditions: Multiple Myeloma

First Posted Date: 2006-05-18

Last Posted Date: 2009-08-11

Lead Sponsor: AmpliMed Corporation

Registration Number: NCT00327249

Locations: 🇺🇸
Investigational Site 025, Little Rock, Arkansas, United States
🇺🇸
Investigational Site 008, Houston, Texas, United States

Safety Study of Imexon Treatment of Patients With Metastatic or Disseminated Malignancy

Phase 1

Completed

Conditions: Neoplasm Metastasis

Interventions: Drug: imexon

First Posted Date: 2006-05-18

Last Posted Date: 2008-03-14

Lead Sponsor: AmpliMed Corporation

Target Recruit Count: 18

Registration Number: NCT00327223

Locations: 🇺🇸
US Oncology, Tyler Cancer Center, Tyler, Texas, United States
🇺🇸
US Oncology Indiana, Indianapolis, Indiana, United States
🇺🇸
US Oncology Albany, New York Oncology, Albany, New York, United States

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy